Not if, but when and how. That’s the conclusion most biopharmaceutical executives have today when it comes to developing a global strategy – increasingly focused on Asia. China likely will be the second-largest pharmaceutical market by 2020, surpassing Japan. Surrounding countries, such as Taiwan and South Korea already have powerful biotechnology and biosimilars subsectors well established. To succeed in today’s global economy, an Asia strategy is not optional.